Andere Sprachen Formycon AG Börse Stuttgart

Aktien

A1EWVY

DE000A1EWVY8

FYB

Markt geschlossen - Börse Stuttgart Andere Börsenplätze 21:55:32 17.05.2024			% 5 Tage	% 1. Jan.
44,05 ^EUR	0,00 %		+2,92 %	-20,77 %

25.04.	Formycon AG meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
15.04.	MORNING BRIEFING - Deutschland/Europa	DJ

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders	16.05.
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region	15.05.
OPINIONI DEGLI ANALISTI DEL GIORNO : Acerinox, Adyen, Brembo, Sabadell, Leonardo, Generali, Enel, IAG, Piaggio, Salvatore Ferragamo, Zalando...	10.05.
AVIS D'ANALYSTES DU JOUR : Legrand, Schneider, Teleperformance, TotalEnergies, Veolia, Worldline, Amundi...	10.05.
OPINIONES DE LOS ANALISTAS DEL DÍA : Acerinox, Caixabank, Endesa, Fluidra, Iberdrola, Telefónica, Endesa, Melia Hotels, IAG, Amundi...	10.05.
Formycon reports on successful operating business and financial figures for the first quarter of 2024	08.05.
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich	07.05.
Formycon hosts conference call on the results of the first quarter 2024	02.05.
DD: Formycon AG: Dr. Marc Mikulcik, buy	29.04.
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	25.04.
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance	25.04.
DD: Formycon AG: Dr. Stefan Glombitza, buy	24.04.
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	22.04.
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024	22.04.
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast	12.04.
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year	12.04.
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)	11.04.
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada	03.04.
Updates On Aflibercept BPCIA Litigation	26.03.
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	18.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Formycon AG: Wachstum trotz starker Konkurrenz im Biosimilar-Markt

Am 19. September 2023 um 20:19 Uhr